Cell Source, Inc.
Data quality: 83%
CLCS
OTC
Manufacturing
Chemicals
$0.84
▲
$0.15
(21.74%)
Mkt Cap: 37.83 M
Price
$0.84
Mkt Cap
37.83 M
Day Range
$0.84 — $0.84
52-Week Range
$0.18 — $2.25
Volume
200
Open $0.84
50D / 200D Avg
$0.86
2.11% below
50D / 200D Avg
$0.54
56.19% above
Quick Summary
Key Takeaways
Negative free cash flow of -2.68 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROIC-873.75%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A
Valuation
PE (TTM)
-8.38
Below sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -8.4 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -4.51 M |
| ROE | N/A | ROA | -1299.67% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -2.68 M |
| ROIC | -873.75% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | N/A | Tangible Book Value | -18.94 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -8.38 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -7.09% | ||
| Market Cap | 37.83 M | Enterprise Value | 37.83 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.14 | Revenue / Share | N/A |
| FCF / Share | -0.06 | OCF / Share | -0.06 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 59.48% |
| SBC-Adj. FCF | -2.99 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -4.51 M | -5.32 M | -5.17 M | -5.47 M | -4.56 M |
| EPS (Diluted) | -0.14 | -0.17 | -0.18 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -3.84 M | -4.33 M | -4.18 M | -4.02 M | -3.64 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | 1.94 M | 1.27 M | 834,943.0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | 629,201.0 | 457,371.0 |
| Income Tax | — | — | — | — | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 286,500.0 | 195,171.0 | 409,845.0 | 313,767.0 | 452,339.0 |
| Total Liabilities | 18.82 M | 15.81 M | 13.04 M | — | 8.40 M |
| Shareholders' Equity | -18.54 M | -15.61 M | -12.63 M | -9.83 M | -7.95 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | — | — | 222,665.0 | 93,095.0 | 245,119.0 |
| Current Assets | — | — | — | 313,767.0 | — |
| Current Liabilities | — | — | — | 10.14 M | 8.40 M |
{"event":"ticker_viewed","properties":{"ticker":"CLCS","listing_kind":"stock","pathname":"/stocks/clcs","exchange":"OTC","country":"US"}}